Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) filed its Monthly Return for Equity Issuer covering the period ended 31 May 2026. Key disclosures are as follows:

• Registered and issued capital unchanged: The company closed May with 622.33 million H-shares in issue, each with a par value of RMB 1. No new shares were issued, cancelled or converted, and no treasury shares were held.

• Public float compliance: Directors confirmed that the company’s public float met the minimum 18.14% level stipulated in the Stock Exchange waiver granted at listing. The over-allotment option from the 2022 IPO was not exercised, and the float remains below the standard 25% requirement but within the approved waiver parameters.

• No outstanding equity instruments: The return shows zero movement in share options, warrants, convertibles or other agreements that could dilute the share base.

The filing, signed by Director Jiang Hua on 3 June 2026, attests that all regulatory obligations under Hong Kong Listing Rules were fulfilled during the reporting month.